Omalizumab for the treatment of severe allergic asthma in children: A tale of two
Abstract Omalizumab is a monoclonal antibody which targets immunoglobulin E. It is approved as an add‐on therapy for children with severe allergic asthma. Assessment of endotype and phenotype is necessary in order to correctly identify those patients who are most likely to respond to omalizumab. Chi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-08-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.6255 |
| _version_ | 1817994630147342336 |
|---|---|
| author | Sinéad Brannick Mary McDonald Peter Greally Basil Elnazir Oneza Ahmareen |
| author_facet | Sinéad Brannick Mary McDonald Peter Greally Basil Elnazir Oneza Ahmareen |
| author_sort | Sinéad Brannick |
| collection | DOAJ |
| description | Abstract Omalizumab is a monoclonal antibody which targets immunoglobulin E. It is approved as an add‐on therapy for children with severe allergic asthma. Assessment of endotype and phenotype is necessary in order to correctly identify those patients who are most likely to respond to omalizumab. Children with severe asthma represent a complex heterogeneous group. This report outlines the background, management, and outcomes for two children initiated on omalizumab for severe allergic asthma in Children's Health Ireland at Tallaght. It demonstrates the difficulties faced by this cohort and the positive impact targeted biological therapy can have. Given the substantial cohort of children with asthma attending our tertiary center, it also indicates that comprehensive stepwise care can achieve adequate control in the vast majority of cases without the requirement for additional therapies. |
| first_indexed | 2024-04-14T01:55:30Z |
| format | Article |
| id | doaj.art-a86c61c55eeb4f3fa4829319fa1e5816 |
| institution | Directory Open Access Journal |
| issn | 2050-0904 |
| language | English |
| last_indexed | 2024-04-14T01:55:30Z |
| publishDate | 2022-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical Case Reports |
| spelling | doaj.art-a86c61c55eeb4f3fa4829319fa1e58162022-12-22T02:19:07ZengWileyClinical Case Reports2050-09042022-08-01108n/an/a10.1002/ccr3.6255Omalizumab for the treatment of severe allergic asthma in children: A tale of twoSinéad Brannick0Mary McDonald1Peter Greally2Basil Elnazir3Oneza Ahmareen4Respiratory Department Children's Health Ireland at Tallaght Tallaght IrelandRespiratory Department Children's Health Ireland at Tallaght Tallaght IrelandRespiratory Department Children's Health Ireland at Tallaght Tallaght IrelandRespiratory Department Children's Health Ireland at Tallaght Tallaght IrelandRespiratory Department Children's Health Ireland at Tallaght Tallaght IrelandAbstract Omalizumab is a monoclonal antibody which targets immunoglobulin E. It is approved as an add‐on therapy for children with severe allergic asthma. Assessment of endotype and phenotype is necessary in order to correctly identify those patients who are most likely to respond to omalizumab. Children with severe asthma represent a complex heterogeneous group. This report outlines the background, management, and outcomes for two children initiated on omalizumab for severe allergic asthma in Children's Health Ireland at Tallaght. It demonstrates the difficulties faced by this cohort and the positive impact targeted biological therapy can have. Given the substantial cohort of children with asthma attending our tertiary center, it also indicates that comprehensive stepwise care can achieve adequate control in the vast majority of cases without the requirement for additional therapies.https://doi.org/10.1002/ccr3.6255allergy and immunologyasthmabiologic therapiespediatrics and adolescent medicinerespiratory medicine |
| spellingShingle | Sinéad Brannick Mary McDonald Peter Greally Basil Elnazir Oneza Ahmareen Omalizumab for the treatment of severe allergic asthma in children: A tale of two Clinical Case Reports allergy and immunology asthma biologic therapies pediatrics and adolescent medicine respiratory medicine |
| title | Omalizumab for the treatment of severe allergic asthma in children: A tale of two |
| title_full | Omalizumab for the treatment of severe allergic asthma in children: A tale of two |
| title_fullStr | Omalizumab for the treatment of severe allergic asthma in children: A tale of two |
| title_full_unstemmed | Omalizumab for the treatment of severe allergic asthma in children: A tale of two |
| title_short | Omalizumab for the treatment of severe allergic asthma in children: A tale of two |
| title_sort | omalizumab for the treatment of severe allergic asthma in children a tale of two |
| topic | allergy and immunology asthma biologic therapies pediatrics and adolescent medicine respiratory medicine |
| url | https://doi.org/10.1002/ccr3.6255 |
| work_keys_str_mv | AT sineadbrannick omalizumabforthetreatmentofsevereallergicasthmainchildrenataleoftwo AT marymcdonald omalizumabforthetreatmentofsevereallergicasthmainchildrenataleoftwo AT petergreally omalizumabforthetreatmentofsevereallergicasthmainchildrenataleoftwo AT basilelnazir omalizumabforthetreatmentofsevereallergicasthmainchildrenataleoftwo AT onezaahmareen omalizumabforthetreatmentofsevereallergicasthmainchildrenataleoftwo |